BioNTech's Q3 Profit Comes With an Asterisk as Roche Cost Shift and Arife Talks Take Shape
Published on 11/03/2026 at 19:40 | Editorial boerse-global.de
BioNTech returned to the black in the third quarter of 2026, but the headline number tells only part of the story. The German biotech posted an IFRS net profit of €184.5 million, a sharp reversal from the €28.7 million loss recorded in the same period a year earlier. Reuters attributes much of that swing to the disappearance of hefty one-off charges tied to legal disputes — a boost to the reported figure that does not, on its own, signal a stronger operating performance.
The adjusted comparison paints a different picture. Stripping out special items, net profit fell to €440.9 million from €752.5 million a year earlier, weighed down by softer vaccine demand and rising research spending. Adjusted earnings per share came in at €1.76, ahead of what analysts had penciled in. Beating consensus, however, is not the same as growing earnings, and the gap between the two measures is what investors will need to weigh.
Revenue for the quarter reached €1.29 billion, down 15% year on year but comfortably above the most recently cited consensus of €1.05 billion. BioNTech pointed to lower demand for COVID-19 vaccines as the driver — a reminder that the legacy business remains under pressure even as the oncology pipeline advances.
Guidance Edges Up at the Bottom
For the full year, the company now expects revenue of €1.7 billion to €1.9 billion, raising the lower bound from €1.6 billion while leaving the top end untouched. Finance chief Ramón Zapata said the quarterly results had pushed the annual expectation toward the upper end of the previously guided range, with investment continuing to concentrate on prioritized oncology programs.
Research remains the dominant cost line. IFRS research and development expense climbed to €748.1 million in the quarter from €564.8 million a year earlier; on an adjusted basis it stood at €578.5 million. The adjusted R&D forecast is unchanged at €2.0 billion to €2.3 billion. Building a broader company is proving expensive, and the quarterly profit should not be read in isolation as proof that the financial turnaround is complete.
Should investors sell immediately? Or is it worth buying BioNTech?
The nine-month picture reinforces that caution. For the first nine months of 2026, BioNTech reported a net loss of €1,168.2 million, wider than the €831.1 million loss in the corresponding prior-year period. Against those outlays, the company held €16.2 billion in cash and securities as of September 30 — ample room to keep funding development.
A Cost-Sharing Reset With Roche
On the pipeline and partnership front, BioNTech announced a changed allocation of future research and development costs for its joint program with Roche/Genentech. From January 1, 2027, those costs are in principle to be borne by Roche/Genentech, with BioNTech potentially receiving royalties if development and commercialization succeed.
Separately, talks are underway over whether BioNTech rights could be contributed to Arife, the new company being planned by BioNTech co-founders U?ur ?ahin and Ă–zlem TĂĽreci, according to a dpa-AFX report.
Mixed Signals From the Clinic
Clinical updates have been similarly two-sided. Roughly a week ago, BioNTech and DualityBio reported that the Phase 3 DYNASTY-Breast02 trial met its primary endpoint. Trastuzumab pamirtecan produced a statistically significant but moderate improvement in progression-free survival versus physician's choice of chemotherapy in HR-positive, HER2-low metastatic breast cancer. Interim overall survival data were not yet mature.
About two weeks earlier, BioNTech agreed with Gilead Sciences to supply sacituzumab govitecan for the Phase 3 ROSETTA Breast-01 study. Subject to regulatory approval, BioNTech and Bristol Myers Squibb plan to replace chemotherapy with this antibody-drug conjugate in the Pumitamig trial, targeting first-line locally advanced or metastatic triple-negative breast cancer with low or absent PD-L1 expression.
Elsewhere, the company said Gotistobart nearly doubled median overall survival compared with chemotherapy in pretreated squamous NSCLC. Such data underpin the oncology strategy, though they do not yet substitute for durable product revenue.
The balance sheet is thus split down the middle: BioNTech beat expectations and nudged its revenue floor higher, while a lower adjusted quarterly profit and a wider nine-month loss show that the earnings turn is not yet secured.
Ad
BioNTech Stock: New Analysis - 3 November
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
